Trump’s August 31 Oval Office announcement centers on new Most-Favored-Nation drug pricing agreements with additional manufacturers, extending the administration’s TrumpRx platform and prior deals that have produced the steepest prescription drug price declines in over six decades. The event builds directly on the January 2026 unveiling of the Great Healthcare Plan, which seeks to codify MFN benchmarks, redirect ACA subsidies to enrollees, increase price transparency, and expand over-the-counter access. Traders focus on recurring rhetorical patterns from earlier remarks—references to specific countries or companies involved in pricing disparities, critiques of prior policies, and emphasis on patient savings—while the market awaits confirmation of any last-minute deal details or phrasing that could trigger specific resolution outcomes.